Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FABP1 | P07148 | 1/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075905 | 0.95 | HSD17B10 (0.51) | HSD17B10CXCR4MEN1KMT2ANPC1 | |
| SCHEMBL14075901 | 0.86 | HSD17B10 (0.45) | HSD17B10FABP1FABP6HPGD | |
| SCHEMBL1413125 | 0.80 | FABP1 (0.67) | CXCR4MEN1KMT2ANPC1RAB9A | |
| Msx-122 SCHEMBL10054965 | 0.80 | CXCR4 (0.61) | CXCR4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28475529 | 0.78 | FABP1 (0.64) | CXCR4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10055053 | 0.78 | ALDH1A1 (0.57) | HSD17B10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10055016 | 0.77 | MAOA (0.58) | CXCR4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL332623 | 0.73 | MAOA (0.63) | HSD17B10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14075895 | 0.72 | TSHR (0.54) | CXCR4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9018848 | 0.72 | CYP1A2 (0.66) | HSD17B10MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| WO-2008008852-A2 | CXCR4 ANTAGONISTS INCLUDING HETEROATOMS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | CXCL12, CXCR4, CXCR1 | HSD17B10 3791/4885CXCR4 2/4885MEN1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.